Intech Investment Management LLC Has $2.66 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Intech Investment Management LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 165.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,421 shares of the company’s stock after acquiring an additional 4,000 shares during the period. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $2,655,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Insight Wealth Strategies LLC raised its holdings in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC grew its position in IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after purchasing an additional 2,241 shares in the last quarter. Quest Partners LLC grew its position in IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new position in IDEXX Laboratories in the third quarter valued at $749,000. Finally, Geode Capital Management LLC grew its position in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock valued at $1,138,732,000 after purchasing an additional 40,349 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $422.15 on Thursday. The company has a 50-day simple moving average of $437.54 and a two-hundred day simple moving average of $445.70. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The stock has a market capitalization of $34.33 billion, a price-to-earnings ratio of 39.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.